What do systematic reviews say?

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.86 [0.67, 1.11]
  1 study · 282 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.56 [0.44, 0.72]
  1 study · 282 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 146 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.92 [0.8, 1.06]
  3 studies · 1250 participants
  Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Chemotherapy with TKI (peptide‐Fc fusion protein) leads to lower progression‐free survival (PFS) compared with chemotherapy alone (high certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.73 [0.65, 0.82]
  3 studies · 1250 participants
  High

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 315 participants
  Low

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in bowel fistula / perforation (grade ≥ 3) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  RR 0.35 [0.01, 8.3]
  1 study · 108 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.99 [0.84, 1.17]
  2 studies · 1451 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.88 [0.77, 1]
  2 studies · 1451 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1340 participants
  Moderate

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 1.25 [0.8, 1.95]
  1 study · 129 participants
  Low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 0.99 [0.69, 1.42]
  1 study · 129 participants
  Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 rash compared with chemotherapy alone (very low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  RR 13.63 [0.78, 236.87]
  1 study · 125 participants
  Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (very low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.16, 2.52]
  1 study · 125 participants
  Very low